ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for transplant patients with rare virus-driven cancer
Disease control Recruiting nowThis study tests a treatment called tabelecleucel for people who develop a rare, virus-related cancer after an organ or stem cell transplant and whose cancer did not respond to standard therapy. The treatment uses specially matched immune cells to fight the cancer. About 115 part…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 17, 2026 05:08 UTC
-
Could a lower dose of transplant drug be just as effective?
Disease control Recruiting nowThis study compares a reduced dose (35mg/kg) versus the standard dose (50mg/kg) of a drug called cyclophosphamide, given after a stem cell transplant to prevent graft-versus-host disease (GVHD). About 316 people receiving a transplant from a matched unrelated or half-matched dono…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:03 UTC